Coya Therapeutics (NASDAQ:COYA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08, Zacks reports. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%.
Coya Therapeutics Stock Performance
Shares of COYA stock traded up $0.05 during mid-day trading on Tuesday, hitting $4.69. 66,023 shares of the stock traded hands, compared to its average volume of 193,667. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75. The company’s 50-day simple moving average is $4.86 and its 200-day simple moving average is $4.67. The firm has a market cap of $109.93 million, a price-to-earnings ratio of -4.08 and a beta of 0.61.
Institutional Investors Weigh In On Coya Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Coya Therapeutics in the 2nd quarter worth approximately $119,000. JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics during the third quarter valued at approximately $28,000. Dauntless Investment Group LLC lifted its stake in Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Coya Therapeutics by 51.3% during the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after buying an additional 22,120 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Coya Therapeutics
About Coya Therapeutics
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
Read More
- Five stocks we like better than Coya Therapeutics
- Oklo’s Revenue Transition Gives Bulls a New Reason to Watch
- Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
- AMD’s Helios Launch Could Create Winners Beyond AMD Stock
- Meta’s Muse Glimmer Release Reframes Its AI Spending Bet
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
